FDA Webview Site FDA Review Site FDA Updater Site
header.gif
Username:
Password:
 

human drugs
animal drugs
biologics
eirs 483s
medical devices
marketing
email
search our site
  
FDA-RELATED NEWS
 
 
 
TXT Stericycle Predicts Surge in FDA Enforcement After Pandemic
05/21/2020
 
 
TXT Teva Abandons Justice Dept Settlement Talks: Report
05/18/2020
 
 
TXT PhRMA Drug Safety Surveillance Comments
05/19/2020
 
 
TXT FDA Posts List of ‘Removed’ Antibody Tests
05/21/2020
 
 
TXT Trump Taking Hydroxychloroquine to Prevent Covid-19
05/18/2020
 
 
TXT QS Violations Seen in Lymol Medical Inspection
05/19/2020
 
 
TXT FDA Improving (Q)SAR Models
05/21/2020
 
 
TXT Trump Wants Drug Pricing Bill, Grassley Says
05/21/2020
 
 
TXT FDA Artificial Intelligence RFI
05/21/2020
 
 
TXT FDA Sentinel Collaboration on Covid Drugs
05/21/2020
 
 
TXT ValeoMD Selling Unapproved Stem Cell Therapy: CBER
05/21/2020
 
 
TXT CDRH Discontinuance, Interruption Notification Explained
05/21/2020
 
 
TXT Phlow Awarded BARDA Generic Drug Contract
05/19/2020
 
 
TXT Since Our Last Issue ...
05/25/2020
 
 
TXT Product Approval Summaries
05/25/2020
 
 
TXT Latest Federal Register Notices
05/25/2020
 
 
TXT Covid Drug Compounding Guidances Updated
05/22/2020
 
 
TXT New Medication Guides for Forms of 10 Drugs
05/22/2020
 
 
TXT 3D Printed Swab Town Hall
05/22/2020
 
 
TXT Covid PMA or HDE Supplement Guidance
05/21/2020
 
 
TXT Comments on Liquid Drug Flow Restrictor Guidance
05/20/2020
 
 
TXT Pandemic Adverse Event Reporting Guidance
05/20/2020
 
 
TXT Groups Issue Facility Device Rep Reentry Guidance
05/20/2020
 
 
TXT Latest FDA Warning Letters
05/19/2020
 
 
TXT Covid Real-World Data Agreement Signed
05/19/2020
 
 
TXT SSS REMS Comments
05/19/2020
 
 
TXT Pharmacovigilance/Risk Management Training Web Cast
05/19/2020
 
 
 
 
The most authoritative FDA news analysis each week is found in the pages of Dickinson's FDA Review. Since 1984, this newsletter has been providing in-depth reports on the most significant FDA developments affecting the pharmaceutical, medical device, biologics and veterinary medicines industries. Unlike other media, FDA Review eliminates time-wasting minutia and presents in clear, concise language the essence of what's really important - and why. It is the publication that FDA officials themselves read. Delivered in the middle of each week, FDA Review presents:
  • The latest agency policy developments, often before they're officially announced;
  • Major news insights, follow-ups and reactions in each product area;
  • Summaries of the latest Warning Letters;
  • The newest product approvals;
  • Summaries of the latest FDA Federal Register notices;
  • Summaries of DDMAC letters;
  • Related industry news capsules;
  • The industry's most concise FDA news index;
  • Inside-FDA news briefs
You can rely on FDA Review to provide only what's important - in the most convenient and time-saving